Results 271 to 280 of about 228,341 (358)

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu   +14 more
wiley   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori   +11 more
wiley   +1 more source

Trends in Rheumatoid Arthritis Mortality Among Postmenopausal Women in the United States, 1999–2023

open access: yesiMetaMed, EarlyView.
RA‐related mortality among U.S. postmenopausal women has markedly declined since 1999. Despite this overall progress, significant inequalities by race, region, and age highlight ongoing challenges in achieving equitable health outcomes. ABSTRACT Rheumatoid arthritis (RA) disproportionately affects postmenopausal women, who are at an increased risk of ...
Yuhui Zhao   +4 more
wiley   +1 more source

Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Sarcoidosis. [PDF]

open access: yesTuberc Respir Dis (Seoul)
Lee EJ   +6 more
europepmc   +1 more source

Isorhamnetin Alleviates Renal Fibrosis Induced by Renal Tubular Epithelial Cell Senescence Via Inhibition of the IL‐6/IL‐6R Signaling Pathway

open access: yesiMetaMed, EarlyView.
IL‐6 from RTECs upregulates TGF‐β in macrophages, promoting fibroblast transdifferentiation. Isorhamnetin inhibits this effect. ABSTRACT Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease.
Weifei Liang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy